PDCD1 and Miyoshi myopathy: However, in June 2017, two related phase three trials (NCT02576977 and NCT02579863) that were evaluating the utility of pembrolizumab (an anti-PD-1 monoclonal antibody) with immunomodulatory drugs (IMiDs: pomalidomide and lenalidomide) for relapsed/refractory MM (RRMM) and newly diagnosed MM (NDMM) were suspended.